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Abstract Our previous studies have shown that the HMG-CoA
reductase (HCR) inhibitor (HCRI), simvastatin, kills L6
myoblasts by involving Ca2+ mobilization from the Ca2+ pool
in the cells but not by influx from extracellular space. More
recently, we found that HCRI induced tyrosine phosphorylation
of several cellular proteins, followed by apoptotic cell death of L6
myoblasts. The present study was aimed to elucidate the
molecular target(s) of these tyrosine phosphorylations induced
by HCRI and demonstrated that simvastatin induces tyrosine
phosphorylation of phospholipase C (PLC) Q1. This tyrosine
phosphorylation of PLC-Q1 caused the increment of the
intracellular inositol triphosphate (IP3) levels in L6 myoblasts.
Pretreatment of the cells with herbimycin A, a specific inhibitor
of protein tyrosine kinase, inhibited a simvastatin-induced
increase in IP3 level in the cells as well as tyrosine phosphoryl-
ation of PLC-Q1. Interestingly, pretreatment of the cells with
U-73122, a specific inhibitor of PLC, prevented simvastatin-
induced cell death. Thus, these results strongly suggest that
simvastatin-induced tyrosine phosphorylation of PLC-Q1 plays,
at least in part, an important role for the development of
simvastatin-induced cell death.
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1. Introduction
3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HCR)
is known to be a rate limiting enzyme in the biosynthesis of
cholesterol. Therefore its inhibitor (HCRI) is a powerful and
widely used medicine for the treatment of hypercholesterole-
mia [1,2]. HCR catalyzes the conversion of HMG-CoA to
mevalonate which is an important precursor of all isopren-
oids. Isoprenoids serve as an important lipid for the normal
post-translational modi¢cation of the membrane-associated
proteins such as Ras and Rho. Lovastatin, a lipophilic
HCRI, is reported to block cell cycling in G1 and G2/M phase
progression and therefore suppresses the growth of tumors in
vitro [3,4]. Our previous studies have revealed that simvasta-
tin, another lipophilic form of HCRI, but not hydrophilic
forms, caused electrical myotonia and muscle cell degenera-
tion in rabbits [5^7]. Although these previous studies disclosed
the possible cytotoxicity of these HCRIs to muscle cells, the
detailed molecular mechanism remained to be elucidated.
In order to explore the molecular sequences of simvastatin-
induced cytotoxicity to muscle cells, we used L6 myoblasts in
culture as a model system, because the L6 myoblasts were
originally developed from rat thigh muscle [8] and have re-
tained the characteristics of skeletal muscle [9]. We have
shown that simvastatin, a lipophilic HCRI, kills L6 myoblasts
by involving intracellular Ca2 mobilization from the Ca2
pool in the cells [5^7]. Our subsequent study disclosed that
simvastatin inhibited the normal post-translational modi¢ca-
tion of the Ras protein, and inhibited phosphatidylinositol
3-kinase (PI 3-kinase) activity followed by the apoptotic cell
death of L6 myoblasts [10,11]. We further found that simvas-
tatin induced rapid tyrosine phosphorylation responses of cel-
lular proteins, which was thought to be an active signal trans-
ducer of cell death [11], although the identity of the target
proteins of tyrosine phosphorylation response remains to be
determined.
Protein tyrosine phosphorylation response mediated by ei-
ther protein kinase(s) or protein tyrosine phosphatase(s) has
been known to play a pivotal role in the intracellular signal
transduction pathway of many extracellular signals for cellu-
lar proliferation and di¡erentiation [12]. It has been suggested
that protein tyrosine phosphorylation is also involved in the
signal transduction of cell death event in blood cancer cells
[13].
In this study, we tried to identify the targets of HCRI-in-
duced tyrosine phosphorylation in L6 myoblasts and found
that phospholipase C (PLC) Q1 is phosphorylated on tyrosine
residue in response to simvastatin treatment with a concom-
itant increase of inositol triphosphate (IP3) level in the cells.
Moreover, pretreatment of the cells with U-73122, a speci¢c
inhibitor of PLC, prevented the occurrence of simvastatin-
induced cell death in L6 myoblasts. These results strongly
suggest that tyrosine phosphorylation of PLC-Q1 and thereby
the activation of PLC-Q1 activity is involved, at least in part,
in the signal transduction pathway of simvastatin-induced cell
death of L6 myoblasts. These results are the ¢rst demonstra-
tion of the essential roles of the tyrosine phosphorylation and
PLC-Q1 activity in the development of muscle cell death.
2. Materials and methods
2.1. Cell culture and treatment
L6 myoblasts (a generous gift from Dr. K. Nakahara, Kagoshima
University School of Medicine, Kagoshima, Japan) were cultured as
monolayers in culture dishes with Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) containing 7.5% fetal calf serum (FCS) and 100 U/
ml penicillin and 100 Wg/ml streptomycin [7]. Cells were treated with
various concentrations of simvastatin (a generous gift from Sankyo
Pharmaceutical Co. Ltd.) for appropriate periods of time at 37‡C.
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Control sister cultures were conducted in a similar way except for the
absence of simvastatin. In some case, cells were incubated with 5 WM
U-73122, a speci¢c inhibitor of PLC, at 37‡C for 1 h and then treated
with 30 Wg/ml simvastatin. For morphological studies, L6 myoblasts
were cultured either in 12-well culture plates or on a cover slip at 37‡C
[14^17].
2.2. Immunoprecipitation and immunoblot analysis
L6 myoblasts were pretreated with or without herbimycin A
(10 WM) for 3 h at 37‡C, and then exposed to 30 Wg/ml simvastatin
for the indicated times. After simvastatin treatment, cells were rinsed
brie£y with chilled phosphate-bu¡ered saline (PBS) containing 1 mM
p-nitrophenylphosphate and lysed with a lysis bu¡er (20 mM HEPES,
pH 7.2/1% Nonidet P-40/10% glycerol/50 mM NaF/1 mM Na3VO4/
10 Wg leupeptin per ml) as described previously [16,17]. Tyrosine
phosphorylated proteins in these cell-free lysates were recovered
with an anti-phosphotyrosine (PY)-conjugated protein A-Sepharose.
PLC-Q1 was immunoprecipitated with an anti-PLC-Q1 antibody from
cell-free lysates (usually 1 mg of protein) as prepared above and an-
alyzed with 7.5% SDS-polyacrylamide gel electrophoresis followed by
the immunoblot analysis with either anti-phosphotyrosine (K-PY) or
anti-PLC-Q1 antibody as described previously [16,17]. Detection of
positive bands in the immunoblot was performed using the ECL de-
tection system (Amersham, UK). Protein concentration of cell-free
lysates was determined using the Bradford reagent (Bio-Rad) with
Q-globulin as a standard [18].
2.3. Intracellular IP3 measurement
For quantitation of IP3 level in the cells, cells were incubated in the
regular medium containing 10 mM LiCl. After 10 min, the medium
was quickly aspirated and replaced with regular medium containing
30 Wg/ml simvastatin. The cells were incubated at 37‡C for the indi-
cated times. In the case of cells pretreated with herbimycin A, cells
were pretreated with 10 WM herbimycin A for 3 h, and processed in
the same way as described above, in the continuous presence of her-
bimycin A in the culture medium. The reaction was terminated by the
addition of ice-cold 10% perchloric acid and then neutralized by the
addition of 75 mM HEPES containing 1.53 M KOH. The solution
was kept on ice for 1 h, transferred from dish to microtube and
centrifuged at 2000Ug for 15 min at 4‡C. The supernatant was then
centrifuged at 12 000Ug for 15 min at 4‡C and the ¢nal supernatant
was subjected to a IP3 assay using a radioreceptor assay kit (Dupont,
USA) as described previously [19]. The amount of IP3 in the test
samples was calculated from the standard curve using authentic
1,4,5-IP3 as speci¢ed in the manufacturer’s protocol.
3. Results
3.1. Morphology
We examined the morphology of simvastatin-treated L6
myoblasts by phase-contrast microscopy. In the absence of
simvastatin, the cells showed a spindle-shaped appearance
with normal nuclei (Fig. 1b) as reported previously [10]. On
the other hand, in the presence of simvastatin, the cells
showed some intracytoplasmic vacuolations and shrinkage
of the cytoplasm (Fig. 1c) at 45 min and (Fig. 1d) at 1 h after
the addition. However, pretreatment of the cells with U-
73122, a speci¢c inhibitor of PLC, rescued the cells from
simvastatin-induced cell death (Fig. 1a).
3.2. Protein tyrosine phosphorylation and immunoblot analysis
Our previous study has shown that simvastatin kills L6
myoblasts by involving intracellular Ca2 mobilization from
intracellular Ca2 pool [7]. Therefore, we hypothesized that
PLC-Q1 is involved in the signal transduction of simvastatin-
induced cell death. TY verify this hypothesis, we immuno-
precipitated tyrosine phosphorylated proteins from cell-free
lysates of simvastatin-treated cells by use of an anti-PY anti-
body-conjugated protein A-Sepharose. These immunoprecipi-
tates were analyzed with immunoblot analysis and probed
with an anti-PLC-Q1 antibody (Fig. 2A). The increasing
amount of PLC-Q1 was present in these immunoprecipitates
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Fig. 1. E¡ect of U-73122, a speci¢c inhibitor of PLC, on the morphology of simvastatin-treated L6 myoblasts. L6 myoblasts were cultured on
a coverslip with regular culture medium and were pre-treated with (a) or without (b^d) 5 WM U-73122 for 1 h at 37‡C. Then the cells were in-
cubated with (a, c, d) or without (b) 30 Wg/ml simvastatin for 45 min (c) and 60 min (a, d). Phase-contrast micrographs made from typical
areas of these cultures. Note that U-73122 shows an inhibitory e¡ect on simvastatin-induced morphological degeneration of the cells.
T. Mutoh et al./FEBS Letters 446 (1999) 91^9492
in a time-dependent manner. We further veri¢ed more directly
whether simvastatin treatment induces tyrosine phosphoryla-
tion of PLC-Q1. We immunoprecipitated PLC-Q1 from cell-
free lysates obtained from L6 myoblasts cultured in the pres-
ence or absence of simvastatin and subjected to immunoblot
analysis with either an anti-PY antibody or an anti-PLC-Q1
antibody. Simvastatin clearly induced tyrosine phosphoryla-
tion of PLC-Q1 as shown in Fig. 2B (compare lanes 1 and
2). Herbimycin A, a speci¢c tyrosine kinase inhibitor, inhib-
ited tyrosine phosphorylation of PLC-Q1 (Fig. 2B, lane 3).
3.3. IP3 formation
To examine whether tyrosine phosphorylation of PLC-Q1
activates its catalytic activity, we measured IP3 level, a prod-
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Fig. 3. Simvastatin-induced IP3 formation in L6 myoblasts. L6 myoblasts wre pretreated with 10 mM LiCl for 10 min, then were treated with
various concentrations of simvastatin for the indicated times. Intracellular IP3 level was measured as described in Section 2 using radioreceptor
assay kit (Dupont New England Nuclear). A: Time course of IP3 production by 30 Wg/ml simvastatin. The data were obtained from three dif-
ferent samples with duplicate assay (mean þ S.D.). B: Dose dependence of IP3 production by simvastatin for 10 min incubation. The data were
obtained from three di¡erent samples with duplicate assay (mean þ S.D.). C: The e¡ect of the herbimycin A pretreatment on simvastatin-in-
duced IP3 production. L6 myoblasts were pretreated with 10 WM herbimycin A for 3 h (3) or without (1, 2) and treated with 30 Wg/ml simvas-
tatin (2, 3), then further processed as described in Section 2. The data were obtained from three di¡erent samples with duplicate assay
(mean þ S.D.). Data represent the percentage against control values (10 pmol/106 cells).
Fig. 2. Simvastatin-induced tyrosine phosphorylation of PLC-Q1. A:
L6 myoblasts were treated with (2^4) or without (1) 30 Wg/ml sim-
vastatin for 2.5 min (2), 10 min (3), and 30 min (4). Tyrosine phos-
phorylated proteins were immunoprecipitated with an anti-phospho-
tyrosine antibody-conjugated protein A-Sepharose (UBI, Lake
Placid, NY, USA) from cell-free lysates (normally 1 mg of protein)
prepared from the cells as described in Section 2. Then the samples
were analyzed with immunoblot, and probed with an anti-PLC-Q1
antibody (Transduction Laboratory, USA). Lines on the left side of
the panel represent positions of molecular weight markers (120 kDa,
98 kDa, 56 kDa, 38 kDa, 28 kDa). B: PLC-Q1 was immunoprecipi-
tated with an anti-PLC-Q1 antibody from cell-free lysates (normally
1 mg of protein) of L6 myoblasts pretreated with (3) or without
(1, 2) 10 WM herbimycin A for 3 h and then stimulated with (2, 3)
or without (1) simvastatin (30 Wg/ml) for 10 min. The resultant sam-
ples were subjected to the immunoblot probed with an anti-phos-
photyrosine antibody. C: The same samples used in B were re-
probed with an anti-PLC-Q1 antibody to measure protein amount of
PLC-Q1 in the immunoprecipitates.
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uct of the enzymatic reaction of PLC-Q1, in the cells. Intra-
cellular IP3 level was increased with simvastatin-treatment in
a dose-dependent and time-dependent manner. Simvastatin
clearly upregulated the intracellular IP3 levels up to 4-fold
over basal level at 10 min after the addition of simvastatin
(Fig. 3A,B). On the other hand, in herbimycin A-pretreated
cells, we could not observe any increase in simvastatin-in-
duced IP3 production in the cells (Fig. 3C).
4. Discussion
Our previous studies have shown that lipophilic HCRIs
such as simvastatin, but not hydrophilic derivatives, induced
muscle cell damage on rabbits and kills L6 myoblasts by in-
volving intracellular Ca2 mobilization [5^7]. The subsequent
study has revealed that simvastatin induced tyrosine phos-
phorylation of cellular proteins and this tyrosine phosphoryl-
ation response acts as a signal transducer of simvastatin-in-
duced apoptotic cell death of L6 myoblasts [11]. Such an
obligatory role of protein tyrosine phosphorylation in the
cell death event has been observed only in blood cells and
ovarian tumor cell systems [13,20^22], although the identity
of protein tyrosine kinase(s) and the target proteins remains
to be elucidated. In this study, we found that PLC-Q1 is a
possible target protein of these tyrosine phosphorylation re-
actions which act as a positive signal transducer for apoptosis.
Heretofore, accumulating evidence has suggested that tyrosine
phosphorylation of PLC-Q1 resulted in the activation of its
enzymatic activity, although this tyrosine phosphorylation of
PLC-Q1 is not the only means of activation [23,24]. For exam-
ple, some kinds of fatty acids and arachidonic acid can acti-
vate the enzymatic activity [25]. These activated PLC-Q1 cata-
lyze IP3 formation and thereby induce Ca2 mobilization of
the Ca2 pool in the cells. In order to verify that tyrosine
phosphorylation of PLC-Q1 actually activates the enzymatic
activity, we measured intracellular IP3 level of simvastatin-
treated cells. We observed an obvious increase in IP3 produc-
tion in response to simvastatin treatment correlated with the
extent of tyrosine phosphorylation of PLC-Q1. As reported
previously, simvastatin induces a rise in the intracellular
Ca2 concentration within 10 min of its addition to the cul-
ture medium [7]. Tyrosine phosphorylation of PLC-Q1 reached
its maximum 10 min after the addition. These time sequences
¢t well the hypothesis that simvastatin activates PLC-Q1 by its
phosphorylation on tyrosine residue(s) and in turn induces
Ca2 release from the intracellular Ca2 pool. These results
strongly suggest that PLC-Q1 can act as a positive signal trans-
ducer of the apoptosis. In fact the pretreatment of the cells
with U-73122, a speci¢c inhibitor of PLC, prevented the oc-
currence of simvastatin-induced apoptotic cell death.
Although we cannot exclude a possible involvement of PLC-
L in these events, this type of PLC isozyme is reported to be
much faster in provoking the Ca2 release from the Ca2 pool
in the cells. Recent reports that PLC-Q2 activation by tyrosine
phosphorylation is necessary for surface immunoglobulin
M-induced B cell apoptosis is consistent with the present re-
sults [26].
Thus, these results indicate that a special role of PLC-Q1 in
the intracellular signal transducing machinery for apoptotic
cell death of muscle cell-derived cell system. We are now ex-
ploring the responsible protein tyrosine kinase(s) acting as the
initiating signal for apoptosis.
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